Correction: Matched-pair analysis of motor outcomes in adults with spinal muscular atrophy on nusinersen vs. risdiplam [0.03%]
关于脊髓性肌萎缩症成人患者在nusinersen与risdiplam治疗下的运动结局配对分析的更正通知
Svenja Neuhoff,Benjamin Stolte,Jaqueline Lipka et al.
Svenja Neuhoff et al.
Published Erratum
Journal of neurology. 2026 Mar 28;273(4):236. DOI:10.1007/s00415-026-13669-5 2026
Clinical features of paraneoplastic neurologic syndromes with anti-Ri antibodies: PRISMA systematic review [0.03%]
抗Ri抗体副肿瘤性神经综合征的临床特征系统回顾(PRISMA)
Yun Chen,Chaoer Wu,Xinlei Liu et al.
Yun Chen et al.
Background and objectives: Paraneoplastic neurological syndromes (PNSs) are a group of neurological disorders linked to malignancies. Their clinical trajectory, differential diagnoses, immune-mediated mechanisms, and outc...
Plasma brain-derived p-tau217 for the identification of amyloid status in a memory clinic cohort [0.03%]
基于记忆门诊队列的血浆脑源性p-tau217用于识别淀粉样蛋白状态
Adam H Dyer,Helena Dolphin,Laura Morrison et al.
Adam H Dyer et al.
Effect of noninvasive brain stimulation for unilateral spatial neglect after stroke: a systematic review and meta-analysis [0.03%]
经颅磁刺激对脑卒中后单侧空间忽略疗效的系统评价和meta分析研究
Ruoxuan Zhao,Tong Hao,Chengshuo Wang et al.
Ruoxuan Zhao et al.
Background: Unilateral spatial neglect (USN) is one of the most common behavioral cognitive impairments after stroke, limiting functional activities and impairing daily life. Increasing evidence suggests that noninvasive ...
Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study [0.03%]
Ponсimid治疗复发性多发性硬化症的长期安全性和疗效：OPTIMUM 5年长期延伸研究结果
Xavier Montalban,Reinhard Hohlfeld,Carlo Pozzilli et al.
Xavier Montalban et al.
Introduction: In phase 3 OPTIMUM study, ponesimod demonstrated superior efficacy and acceptable safety vs teriflunomide in participants with relapsing multiple sclerosis (RMS). This long-term extension (LTE) study was des...
Clinical Trial
Journal of neurology. 2026 Mar 25;273(4):234. DOI:10.1007/s00415-026-13675-7 2026
Assessing respiratory status in myasthenia gravis: limited value of the MG-ADL as a standalone tool compared with spirometry in a Danish cohort [0.03%]
丹语人群队列中重症肌无力患者呼吸功能评估：仅使用MG-ADL量表的局限性及与肺功能指标比较研究
Linda Kahr Andersen,Simone Birnbaum,Malene Missel et al.
Linda Kahr Andersen et al.
Background: Patients with generalized Myasthenia Gravis (gMG) may develop respiratory involvement, which can be life-threatening. In clinical practice, the Myasthenia Gravis Activities of Daily Living scale (MG-ADL) is of...
Comparative Study
Journal of neurology. 2026 Mar 24;273(4):231. DOI:10.1007/s00415-026-13757-6 2026
Treatment-related modulation of visuo-vestibular integration in post-earthquake dizziness syndrome: a longitudinal virtual reality-based study [0.03%]
基于纵向虚拟现实研究的治疗相关视觉前庭整合在地震后头晕综合征中的调节作用
Hanifi Korkmaz,Işıl Çakmak Karaer,Kübra Orman et al.
Hanifi Korkmaz et al.
Background: Post-earthquake dizziness syndrome (PEDS) is increasingly recognized as a condition marked by persistent dizziness and imbalance after major earthquakes, often without clear peripheral vestibular pathology. De...
Crossed cerebellar diaschisis on CT perfusion in large vessel occlusion stroke: early predictors and clinical relevance in the hyperacute phase [0.03%]
大型血管闭塞卒中CT灌注交叉小脑功能丧失的早期预测因素及超急性期临床意义
Marcello Naccarato,Edoardo Ricci,Giovanni Furlanis et al.
Marcello Naccarato et al.
Background and purpose: Crossed cerebellar diaschisis (CCD) is a pathophysiological phenomenon in ischemic stroke (IS) that remains poorly investigated, particularly with regard to its clinical impact and the factors asso...
Half a century of change: demographic trends and their clinical impact in acetylcholine receptor antibody-positive myasthenia gravis [0.03%]
百年变迁：乙酰胆碱受体抗体阳性重症肌无力的流行病学及临床特征变化趋势分析
Silvia Falso,Gregorio Spagni,Gabriele Monte et al.
Silvia Falso et al.
Background: The impact of myasthenia gravis (MG) changing epidemiology on disease management remains unclear. We investigated how MG subtypes changing over the last 50 years have affected disease prognosis. ...
Agathe Vrillon,Karl Götze,Julien Dumurgier et al.
Agathe Vrillon et al.
Introduction: Anti-amyloid monoclonal antibodies, including lecanemab and donanemab, are now available for the treatment of Alzheimer's disease (AD). Defining real-world patient eligibility and identifying barriers to acc...
Observational Study
Journal of neurology. 2026 Mar 23;273(4):228. DOI:10.1007/s00415-026-13760-x 2026